Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 - Hepion Pharmaceuticals (NASDAQ:HEPA)

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for

Related Keywords

Austria ,Vienna ,Wien ,United States ,Stephen Kilmer ,Drug Administration ,Exchange Commission ,International Liver Congress ,Hepion Pharmaceuticals ,Hepion Pharmaceuticals Investor Relations ,Scripps Research ,Hepion Pharmaceuticals Inc ,Hepion Pharmaceuticals Research ,Scripps Research Institute Winston Stauffer ,European Association ,Scripps Research Institute ,Winston Stauffer ,Chief Scientific Officer ,Daren Ure ,Fast Track ,Orphan Drug ,Artificial Intelligence ,Private Securities Litigation Reform Act ,Hepion Pharmaceutical ,Hepion Pharmaceutical Form ,